CD274 and neoplasm: While tumoral PD-L1 expression was assessed in most clinical trials investigating anti-PD-1/PD-L1 ICIs, PD-L1 level of tumor-infiltrating immune cells was also evaluated in atezolizumab’s trials [POPLAR (25) and OAK (11)].